What does CagriSema do?

Your body has multiple systems that tell your brain "I'm full." GLP-1 is one. Amylin is another. Current drugs like Ozempic only target GLP-1. CagriSema targets both.

Semaglutide (the GLP-1 part) slows your stomach and reduces appetite. Cagrilintide (the amylin part) tells your brain's satiety centre that you've eaten enough, reduces glucagon (a blood sugar-raising hormone), and further slows digestion. The result: more weight loss than either drug alone.

Who is it for?

• People with severe obesity (BMI 35+) who haven't achieved enough weight loss with GLP-1 alone
• Those considering bariatric surgery — CagriSema may offer a non-surgical alternative for some
• Type 2 diabetes patients who also need significant weight reduction

CagriSema is not yet approved, so it's currently only available through clinical trials.

How it's taken

India context

• Novo Nordisk in India: Already sells Ozempic and Wegovy in India. Their distribution network is established, which could speed up CagriSema's launch.
• Timeline: Regulatory submissions are underway. If approved globally in 2026–2027, Indian availability could follow by 2027–2028.
• Expected cost: Likely to be among the most expensive GLP-1 options initially — potentially ₹30,000–50,000+ per month. Generic versions would be years away.
• Bariatric surgery comparison: India performs ~50,000+ bariatric surgeries per year. A drug achieving similar weight loss could reshape this landscape.

Frequently Asked Questions

How it works in your body

Amylin is a peptide hormone released alongside insulin from your pancreatic beta cells after meals. It has three main effects: it slows gastric emptying, suppresses glucagon (which prevents your blood sugar from spiking), and signals satiety to your brain's area postrema.

Cagrilintide is a long-acting amylin analog designed for weekly dosing. When combined with semaglutide, you get appetite suppression from two independent pathways — GLP-1 receptors and amylin receptors. This dual coverage likely explains why the weight loss exceeds what either drug achieves on its own.

What the trials show

• REDEFINE-1 (obesity): ~22.7% mean body weight loss at 68 weeks vs ~15.8% for semaglutide alone and ~2.3% for placebo.
• REDEFINE-2 (T2 diabetes + obesity): Superior HbA1c reduction and weight loss vs semaglutide alone in diabetic patients.
• Muscle preservation: Early data suggests the weight loss composition (fat vs muscle) is similar to semaglutide alone — about 60–70% fat mass and 30–40% lean mass.
• Tolerability: GI side effect rates were comparable to semaglutide alone, which was a positive surprise — adding cagrilintide didn't meaningfully increase nausea or vomiting.

Side effects & safety

The side effect profile is largely driven by the semaglutide component:

• Nausea — most common, 25–35% during dose escalation. Same pattern as Ozempic.
• Vomiting — 8–15% during titration. Resolves for most people.
• Diarrhea — roughly 15%. Generally mild.
• Constipation — less common but reported, possibly related to the amylin component slowing gastric motility.
• Injection site reactions — mild redness, bruising, or itching. Similar to other weekly injectables.
• Decreased appetite — expected and therapeutic, but can lead to inadequate nutrition if protein intake isn't maintained.

Who should be cautious: Same contraindications as semaglutide — avoid if you have a history of medullary thyroid carcinoma or MEN2 syndrome. People with a history of pancreatitis should discuss risks with their doctor.

Related